Zomedica Corp. (ZOM)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Zomedica Corp. (ZOM) trades at $0.10 with AI Score 54/100 (Grade B). Zomedica Corp. is a veterinary health company focused on developing innovative diagnostic and therapeutic products for companion animals. Market cap: $95.35M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for ZOM: ZOM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ZOM against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ZOM: 3/7 perspectives are bearish. Dominant signal: Jim Simons bearish.
How is this calculated? →Zomedica Corp. (ZOM) Healthcare & Pipeline Overview
Zomedica Corp. specializes in veterinary health, offering cutting-edge diagnostic and therapeutic solutions for companion animals, including its TRUFORMA platform and PulseVet technology, positioning itself as a leader in addressing the clinical needs of veterinarians.
What Is the Investment Thesis for ZOM?
Zomedica Corp. presents a unique investment thesis driven by its innovative product offerings and strategic collaborations. The TRUFORMA platform is expected to capture significant market share in the growing veterinary diagnostics sector, projected to reach $2 billion by 2027. As the company continues to enhance its product portfolio through partnerships with Celsee and Seraph Biosciences, it is well-positioned to leverage the increasing demand for advanced veterinary diagnostics and therapeutics. However, Zomedica faces risks such as regulatory hurdles and competition from established players in the veterinary health market. Its current profit margin stands at -65.8%, indicating the need for operational improvements to achieve profitability. Investors should closely monitor the company's progress in product development and market penetration as key drivers of future growth.
Based on FMP financials and quantitative analysis
ZOM Key Highlights
- Market Cap of $95.35M reflects the company's current valuation in the veterinary health sector.
- Gross Margin of 66.3% indicates strong potential for profitability as revenue scales.
- Profit Margin of -65.8% highlights the need for operational improvements and cost management.
- Beta of 1.16 suggests a slightly higher volatility compared to the overall market.
- No dividend yield as the company reinvests earnings into growth initiatives.
Who Are ZOM's Competitors?
ZOM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| IDXX IDEXX Laboratories, Inc. | $564.98 | +1.29% | $44.57B | 93 |
| VIVO Meridian Bioscience, Inc. | $4.81 | +2.78% | $80.76M | 54 |
| ZTS Zoetis Inc. | $75.28 | +0.64% | $31.56B | 84 |
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ZOM's Key Strengths?
- Innovative product portfolio addressing critical needs in veterinary health.
- Strong gross margins indicating potential for profitability.
- Strategic collaborations enhancing product development capabilities.
- Focus on companion animals, a growing market segment.
What Are ZOM's Weaknesses?
- Current negative profit margin indicating financial challenges.
- Limited brand recognition compared to larger competitors.
- Dependence on a small number of key products for revenue generation.
- Need for operational improvements to achieve sustainable growth.
What Could Drive ZOM Stock Higher?
- Launch of new diagnostic products from the TRUFORMA platform expected in Q4 2026.
- Collaboration with Celsee, Inc. to develop liquid biopsy assays for cancer detection.
- Continued development of the PulseVet technology for musculoskeletal treatments.
- Expansion into new geographic markets planned for 2027.
- Increasing demand for veterinary diagnostics due to rising pet ownership trends.
What Are the Key Risks for ZOM?
- Negative return on equity (-19.2%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles could delay product approvals and market entry.
- Competition from established veterinary health companies may impact market share.
- Economic downturns could reduce consumer spending on veterinary services.
- Dependence on a limited product range may expose the company to revenue volatility.
What Are the Growth Opportunities for ZOM?
- Expansion of TRUFORMA Platform: The TRUFORMA platform is poised for growth as the demand for point-of-care diagnostics in veterinary practices increases. With the global veterinary diagnostics market expected to reach $2 billion by 2027, Zomedica's innovative diagnostic solutions can capture a significant share, particularly in the areas of endocrinology and infectious diseases.
- Partnerships for Liquid Biopsy Assays: Zomedica's collaboration with Celsee, Inc. for developing liquid biopsy assays presents a substantial growth opportunity. As the market for cancer diagnostics in companion animals expands, Zomedica can leverage this partnership to introduce cutting-edge solutions, addressing a critical need in veterinary oncology.
- Development of Novel Pathogen Detection Systems: The partnership with Seraph Biosciences, Inc. to develop a novel pathogen detection system aligns with the growing emphasis on disease prevention in veterinary medicine. This innovative technology could enhance Zomedica's product portfolio and provide veterinarians with essential tools for early detection and management of infectious diseases.
- Market Penetration in Equine Health: The PulseVet technology addresses musculoskeletal issues in horses and small animals, tapping into the lucrative equine health market. As the demand for advanced treatment options in equine medicine rises, Zomedica can expand its reach and capture new customer segments.
- Increased Focus on Animal Health and Wellness: The overall trend towards improved animal health and wellness presents a favorable environment for Zomedica's growth. With pet owners increasingly willing to invest in their pets' health, Zomedica's innovative products can meet the rising demand for effective veterinary solutions.
What Opportunities Does ZOM Have?
- Expansion of the veterinary diagnostics market driven by increasing pet ownership.
- Growing demand for advanced therapeutic solutions in veterinary medicine.
- Potential to leverage partnerships for innovative product development.
- Increased focus on animal health and wellness presents new market opportunities.
What Threats Does ZOM Face?
- Intense competition from established players in the veterinary health market.
- Regulatory challenges in bringing new products to market.
- Economic downturns affecting pet owners' willingness to spend on veterinary care.
- Rapid technological advancements necessitating continuous innovation.
What Are ZOM's Competitive Advantages?
- Innovative product offerings that address specific unmet needs in veterinary medicine.
- Strong partnerships with companies like Celsee and Seraph Biosciences enhance product development.
- Focus on point-of-care diagnostics provides a competitive edge in the veterinary market.
- Established brand recognition within the veterinary health community.
- Commitment to research and development fosters continuous innovation.
What Does ZOM Do?
Founded in 2015 and headquartered in Ann Arbor, Michigan, Zomedica Corp. is a pioneering veterinary health company dedicated to addressing the unmet needs of clinical veterinarians. The company was originally known as Zomedica Pharmaceuticals Corp. but rebranded to Zomedica Corp. in October 2020 to better reflect its focus on veterinary health. Zomedica develops and commercializes innovative products designed specifically for companion animals, with a strong emphasis on diagnostics and treatment solutions. One of its flagship products is the TRUFORMA platform, which provides point-of-care diagnostic products tailored for disease states in dogs and cats, enabling veterinarians to make informed decisions quickly. Additionally, Zomedica offers PulseVet, a technology that addresses various musculoskeletal issues in horses and small animals, such as broken bones, tendonitis, and torn ligaments. The company has also established strategic collaboration agreements with Celsee, Inc. for the development of liquid biopsy assays aimed at cancer detection in companion animals, and with Seraph Biosciences, Inc. to develop a novel pathogen detection system. These collaborations enhance Zomedica's product offerings and expand its market reach, positioning it favorably within the veterinary healthcare sector.
What Products and Services Does ZOM Offer?
- Develops innovative diagnostic products for companion animals through the TRUFORMA platform.
- Offers therapeutic solutions for musculoskeletal issues in horses and small animals via PulseVet technology.
- Engages in strategic collaborations to enhance product offerings and expand market reach.
- Focuses on addressing unmet clinical needs in veterinary medicine.
- Targets the growing veterinary diagnostics and therapeutics market.
- Strives to improve the quality of care for companion animals through advanced technologies.
How Does ZOM Make Money?
- Generates revenue through the sale of diagnostic and therapeutic products for veterinary practices.
- Collaborates with other companies to develop and commercialize innovative veterinary health solutions.
- Focuses on point-of-care diagnostics that enable veterinarians to make timely decisions.
- Targets both small animal and equine markets to diversify revenue streams.
- Invests in research and development to enhance product offerings and drive future growth.
What Industry Does ZOM Operate In?
The veterinary health industry is experiencing significant growth, driven by increasing pet ownership and a rising focus on animal health and wellness. The global veterinary diagnostics market is projected to grow at a CAGR of 8.5%, reaching approximately $2 billion by 2027. Zomedica Corp. operates within this expanding market, focusing on innovative solutions that cater to the needs of veterinarians. The competitive landscape includes established players in veterinary diagnostics and therapeutics, but Zomedica's unique offerings, such as TRUFORMA and PulseVet, position it favorably to capture market share.
Who Are ZOM's Key Customers?
- Veterinary clinics and hospitals providing care for companion animals.
- Veterinarians seeking advanced diagnostic and therapeutic solutions.
- Pet owners looking for effective health management options for their animals.
- Equine health practitioners treating horses and other large animals.
- Research institutions focused on veterinary health and diagnostics.
Company Profile
Zomedica Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Ann Arbor, US. The company is led by CEO Larry C. Heaton II. ZOM has traded publicly since 2017.
How Zomedica Corp. Is Valued
Zomedica Corp. carries a market capitalization of $95.35M, placing it in the micro-cap category. Relative to its peer group, ZOM's quantitative score of 54/100 is below the peer average of 74/100.
ROE -19%Key Financial Metrics
Return on equity for Zomedica Corp. stands at -19.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -18.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -17.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.01 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -23.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Zomedica Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.02 places it in the grey zone, a middle ground that warrants monitoring.
ZOM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Zomedica's strategic direction, indicating potential for growth.
- Community sentiment has shifted positively as discussions around product launches gain momentum.
- Increased interest from retail investors reflects a growing belief in Zomedica's market potential and innovation.
- Recent partnerships in veterinary diagnostics highlight the company's commitment to expanding its footprint in a niche market.
Bear Case
- Concerns persist regarding Zomedica's ability to achieve sustained revenue growth amidst competitive pressures.
- Market perception remains cautious due to previous delays in product rollouts, which may affect investor trust.
- Bearish sentiment has emerged as some community members question the scalability of Zomedica's business model.
- Ongoing regulatory challenges in the healthcare sector could create uncertainty for Zomedica's future prospects.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ZOM Latest News
ZOM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ZOM.
Price Targets
Wall Street price target analysis for ZOM.
ZOM MoonshotScore
What does this score mean?
The MoonshotScore rates ZOM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Larry C. Heaton II
CEO
Larry C. Heaton II has extensive experience in the healthcare and life sciences sectors. He has held various leadership roles in both public and private companies, focusing on strategic growth and operational excellence. His educational background includes a degree in business administration, which has equipped him with the skills necessary to lead Zomedica Corp. in its mission to innovate veterinary health.
Track Record: Under Larry's leadership, Zomedica has successfully launched the TRUFORMA platform and established key partnerships to enhance its product offerings. His strategic vision has positioned the company to capitalize on growth opportunities within the veterinary diagnostics market.
ZOM Healthcare Stock FAQ
What does Zomedica Corp. do?
Zomedica Corp. is a veterinary health company that develops innovative diagnostic and therapeutic products specifically for companion animals. Its key offerings include the TRUFORMA platform for point-of-care diagnostics and PulseVet technology for treating musculoskeletal issues in animals. Through strategic collaborations, Zomedica aims to address unmet clinical needs in veterinary medicine.
What are the main risks for ZOM?
Zomedica Corp. faces several risks, including regulatory hurdles that could delay product approvals and market entry, as well as intense competition from established players in the veterinary health market. Additionally, economic downturns may reduce consumer spending on veterinary services, impacting revenue. The company's dependence on a limited product range could also expose it to revenue volatility.
How does Zomedica Corp. navigate regulatory approval processes?
Zomedica Corp. is committed to adhering to regulatory standards set by authorities such as the FDA. The company actively engages in preclinical and clinical trials to ensure its products meet safety and efficacy requirements. By maintaining a robust compliance strategy, Zomedica aims to streamline the approval process for its innovative veterinary health solutions.
What are the key factors to evaluate for ZOM?
Zomedica Corp. (ZOM) holds an AI score of 54/100 (moderate). Not financial advice.
How frequently does ZOM data refresh on this page?
ZOM prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ZOM's recent stock price performance?
Zomedica Corp. (ZOM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product portfolio addressing critical needs in veterinary health. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ZOM overvalued or undervalued right now?
Valuing Zomedica Corp. (ZOM) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ZOM?
Before investing in Zomedica Corp. (ZOM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on available data and is subject to change as new information becomes available.